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Abstract
The major histocompatibility complex (MHC) on chromosome 6p is an established risk locus for
ulcerative colitis (UC) and Crohn’s disease (CD). We aimed to better define MHC association
signals in UC and CD by combining data from dense single nucleotide polymorphism (SNP)
genotyping and from imputation of classical HLA types, their constituent SNPs and corresponding
amino acids in 562 UC, 611 CD, and 1,428 control subjects. Univariate and multivariate
association analyses were performed, controlling for ancestry. In univariate analyses, absence of
the rs9269955 C allele was strongly associated with risk for UC (P = 2.67×10−13). rs9269955 is a
SNP in the codon for amino acid position 11 of HLA-DRβ1, located in the P6 pocket of the HLA-
DR antigen binding cleft. This amino acid position was also the most significantly UC-associated
amino acid in omnibus tests (P = 2.68×10−13). Multivariate modeling identified rs9269955-C and
13 other variants in best predicting UC versus control status. In contrast, there was only suggestive
association evidence between the MHC and CD. Taken together, these data demonstrate that
variation at HLA-DRβ1, amino acid 11 in the P6 pocket of the HLA-DR complex antigen binding
cleft is a major determinant of chromosome 6p association with ulcerative colitis.
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Introduction
The major histocompatibility complex (MHC) on chromosome 6p contains the highly
polymorphic human leukocyte antigen (HLA) genes and other immunoregulatory genes.1, 2
Genetic variants in the MHC have been associated with susceptibility for many infectious
and immune-mediated diseases including the inflammatory bowel diseases (IBD), ulcerative
colitis (UC) and Crohn’s disease (CD).3, 4 Features of the MHC such as dense gene
clustering with broad linkage disequilibrium, extensive polymorphism, and heterogeneity
among different populations have made localization of causal variants challenging.2
HLA polymorphisms were the focus of attention in several IBD candidate gene association
studies of relatively small sample size and meta-analyses of these studies found HLA
associations in UC that were mostly different from those found in CD.3–5 Subsequently,
linkage between IBD and the chromosome 6p IBD3 locus was found in genome-wide
linkage scans6–8. Recent genome-wide association studies (GWAS) have confirmed the
MHC as one of 47 UC loci and 71 CD loci with significant evidence for association (P <
5×10−8).9, 10 The most significant association signal in a recent meta-analysis of six GWAS
that included 6,687 UC cases and 19,718 controls of European ancestry was at a single
nucleotide polymorphism (SNP) in the MHC class II region (rs9268853, P = 1.35×10−55).10
In contrast, the most significant MHC association signal in a meta-analysis of six CD
GWAS that included a similar combined sample size (6,333 CD cases and 15,056 controls)
was less significant than the UC signal and was located in the MHC class III region near the
lymphotoxin A (LTA) locus (rs1799964, P = 3.98×10−11).9, 10
Here, we explore the MHC association signal in the discovery stage of a new UC and CD
GWAS with excellent coverage (>10,000 SNPs) across the extended MHC. We used our
MHC SNP data and an existing reference dataset to impute classical HLA allele types, their
constituent SNPs, and corresponding amino acids in our UC, CD and control samples. This
allowed us to evaluate if the observed SNP associations in the MHC can be explained by
variation specifically in the classical HLA genes.
Results
Analysis of genotyped MHC SNPs in IBD
First, we tested 10,347 genotyped SNPs in the MHC region from 29,299 to 33,884 kb on
chromosome 6 using NCBI36/hg18 coordinates for association with UC and CD with ileal
involvement. Among 35 SNPs that reached genome-wide significance (P < 5 × 10−8) in the
UC analysis, the most significant SNP was rs2647025 (OR=1.95 [1.62–2.35, 95%
confidence interval (CI)] for the G allele; P = 1.94×10−12), located in the promoter region of
HLA-DQB1 (Figure 1A). This SNP is correlated with rs9268853 (r2 = 0.63 in HapMap 3-
CEU11), which was the MHC region SNP with the most significant association in a recent
UC GWAS meta-analysis10, and it is also correlated with rs2395185 (r2 = 0.60 in our
dataset), which was the MHC region SNP with the most significant association in the
NIDDK IBD Genetics Consortium UC GWAS12, both at distances of > 200 kb.
In contrast, there was only suggestive evidence for association between MHC region SNPs
and CD with ileal involvement (Figure 2). The most significant association signal was found
at rs17880124 (OR=2.23 [1.52–3.27, 95%CI] for the G allele; P = 3.82×10−5) which is
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tlocated in an exon of the MHC class I polypeptide-related sequence A (MICA) gene. Of
note, the association observed in UC was many orders of magnitude stronger than that in CD
with ileal involvement despite a similar number of cases. Therefore, we focused on the UC
signal through imputation of classical HLA alleles and their corresponding nucleotide and
amino acid sequences.
Analysis of imputed classical HLA alleles in UC
The following imputed genetic markers were included in our UC vs. control analyses: 156
classical HLA alleles at four-digit resolution, 95 classical HLA allele groups at two-digit
resolution, 1,765 binary SNP features at 1,573 nucleotide positions, and 561 binary HLA
amino acid features at 357 amino acid positions. The most significant association signal in
UC mapped to rs9269955 (Figure 1B), which is a tri-allelic SNP within the coding region of
HLA-DRB1 (position 32,660,116 using NCBI36/hg18 coordinates). In combination with the
nucleotide position directly adjacent to it (rs17878703 at position 32,660,115), rs9269955
determines the codon for amino acid position 11 of the HLA-DRβ1 protein, where six
different amino acid alleles are observed in the population at large (Table 1). Chromosome 6
position 32,660,114 is the third position in this codon, and it is not known to be
polymorphic. Rs9269955-C (to indicate the presence of the C allele) is associated with
protection against UC (OR = 0.51 [0.43–0.61, 95% CI], P = 2.67×10−13). In combination
with the adjacent rs17878703 alleles, rs9269955-C encodes three of the six observed amino
acids (aspartic acid, valine, or glycine) at HLA-DRβ1 amino acid 11 (Table 1). This SNP is
correlated with rs2395185 (r2 = 0.88 in our dataset), which was the MHC region SNP with
the most significant association in the NIDDK IBD Genetics Consortium UC GWAS.12
To analyze the role of specific amino acid positions in the HLA genes in UC, we conducted
omnibus tests for association with degrees-of-freedom equal to the number of distinct
residues for that amino acid position minus one (Table 2). The most significant finding was
for HLA-DRβ1 amino acid 11 (P = 2.68×10−13), consistent with the results noted above
(Figure 1C). Several other amino acid associations were highly significant including other
amino acid positions in HLA-DRβ1, HLA-DQα1 or HLA-DQβ1 (Table 2).
Because these results highlighted HLA-DRβ1 amino acid 11, we further analyzed the six
amino acids at this position and the corresponding classical HLA-DRB1 allele groups at
two-digit resolution (Table 3). The three amino acids (aspartic acid, valine, and glycine)
encoded by the rs9269955-C allele in combination with the adjacent rs17878703 alleles, are
all associated with protection against development of UC.
Among 28 imputed classical HLA-DRB1 alleles tested at four-digit resolution, three were
significantly associated with UC (DRB1*15:01, OR = 1.59 [1.31–1.93, 95% CI], P =
3.68×10−6; DRB1*01:03, OR = 38.39 [7.50–196.60, 95% CI], P = 1.20×10−5; DRB1*07:01,
OR = 0.61 [0.48–0.77, 95% CI] P = 3.38×10−5).
Because the above findings highlighted HLA-DRB1 association in UC, we then evaluated
the quality of our classical HLA-DRB1 allele imputation at two-digit resolution by
performing HLA-DRB1 genotyping via SSO probes and also next-generation sequencing
using genomic DNA from 384 of our study subjects. This analysis demonstrated that the
imputation procedure we applied was 98.8% accurate (see Supplementary Materials).
We next determined the most parsimonious model to explain the association of HLA-DRβ1
amino acid 11 with UC using forward stepwise model selection for the six observed amino
acids. The best model included only three of the six amino acids: valine, glycine and aspartic
acid. The overall P value for this best model was 3.60×10−13 as compared to a P value of
2.68×10−13 for the full model that included all six amino acid alleles, suggesting that most
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tof the association signal for UC at this position can be accounted for by only these three
amino acids. Of note, valine, glycine and aspartic acid are the same three amino acids
encoded by the most significant SNP allele, rs9269955-C, when it is combined with the
adjacent rs17878703 SNP alleles. This provides good internal validation between these
different analytic approaches and highlights that variation at HLA-DRβ1 amino acid 11
explains much of the HLA association with UC.
UC versus control best multivariate model
When we performed analyses conditioned on including either rs9269955-C or the HLA-
DRβ1 amino acid 11 variants, there were residual UC versus control association signals due
to effects of other variants in the HLA region. This finding is consistent with prior
observations in UC that multiple independent association signals exist in the MHC. We used
a forward stepwise model selection procedure to select the best set of markers to predict UC
(Table 4). This best model has an overall P value of 4.28×10−40 and includes rs9269955-C
and 13 other markers that span the chromosome 6 region from 29.45 to 33.81 Mb.
UC versus CD with ileal involvement best multivariate model
In order to compare HLA associations between UC and CD with ileal involvement, we
performed an analysis using UC subjects as cases and CD with ileal involvement subjects as
controls. Initial association analyses for all markers in our study were performed and then
we applied stepwise model selection to determine the best model for a UC versus CD with
ileal involvement comparison (Table 5A). The model that was selected included 11 markers
and had an overall model P value of 4.48×10−33. Not unexpectedly, there was no overlap
between these markers and those that were chosen in the UC versus control best model
described above (Table 4).
We then used the 11 markers from the UC versus CD with ileal involvement best model to
perform two further analyses: UC versus control and CD with ileal involvement versus
control (Tables 5B and 5C). The model P value for UC versus control was 1.59×10−19
which is less significant than the P value of 4.28×10−40 for the unrestricted UC best model
(Table 4). The model P value for CD with ileal involvement versus control was 1.42×10−5.
Divergent effects for each UC versus CD with ileal involvement best model marker in the
UC versus control compared to the CD with ileal involvement versus control analyses are
apparent when the odds ratios for each marker are compared.
Discussion
The MHC locus demonstrates the strongest evidence for association to UC among 47 well-
established UC loci identified in a GWAS meta-analysis10, and is also one of 71 well-
established CD loci identified by GWAS meta-analysis.9 In order to better understand MHC
association signals in UC and CD, we used dense MHC SNP data from the discovery stage
of an ongoing, new UC and CD GWAS to impute classical HLA types, their constituent
SNPs and corresponding amino acids, and we performed detailed analyses of the genotyped
and imputed data.
Our univariate tests of binary SNP and SNP allele markers, and our omnibus tests of
polymorphic HLA amino acid positions both highlighted HLA-DRβ1, amino acid position
11 as the MHC feature most significantly associated with UC. The C allele of rs9269955
was the SNP allele most significantly associated with UC (presence of rs9269955-C is
associated with protection and absence is associated with risk for UC). In combination with
the immediately adjacent SNP, it encodes the valine, glycine or aspartic acid amino acid
residues at HLA-DRβ1, amino acid 11, which were all associated with protection against
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tUC. Furthermore, in multivariate analysis, the most parsimonious model to explain the
association with UC at amino acid 11 consisted of valine, glycine and aspartic acid as the
only terms.
HLA-DRB1 has extensive polymorphism as demonstrated by its 928 alleles and the 704
proteins for which it codes (International Immunogenetics Information System/HLA
Database: http://www.ebi.ac.uk/imgt/hla)13. Valine at amino acid 11 corresponds to the
common DRB1*04 (DR4) or lower frequency DRB1*10 (DR10) allele groups, glycine to
DRB1*07 (DR7), and aspartic acid to DRB1*09 (DR9). The HLA-DR4, -DR7 and -DR9
allele groups were associated with protection against UC in a meta-analysis of prior studies.3
They almost always occur on haplotypes carrying the HLA-DRB4 gene which encodes the
DR53 antigen, and HLA-DRB4*01:01 has been associated with protection against UC in
Japan.14 In addition, the previously reported HLA-DR2 association with risk for UC3, 5 is
consistent with our observation that proline at position 11 in HLA-DRβ1 is associated with
risk for UC. Based on the complementary findings from our different analyses and their
correlation with results from prior studies, we conclude that variation at amino acid position
11 of HLA-DRβ1 is a major determinant of chromosome 6p association with ulcerative
colitis.
The potential biological significance of the UC association of amino acid position 11 relates
to the peptide binding specificity of HLA class II molecules and their role in antigen
presentation to T cells.15, 16 The three-dimensional structure of the class II molecule HLA-
DR1 heterodimer (DRA/DRB1*0101) has been well characterized and its peptide binding
groove has been shown to be determined by polymorphic molecules that form nine pockets
with different chemical and size characteristics.15, 17 In one of these pockets (P6), amino
acid position 11 appears to be the only variable residue and thus determines the binding
specificity of that pocket.18 Of note, hydrophobic amino acid residues at DRβ1 amino acid
11 were found to be associated with protection against development of sarcoidosis.19 This
finding suggests that such hydrophobic interactions could affect peptide binding in the P6
pocket.19 We therefore hypothesize that variation at the amino acid position 11 of HLA-
DRβ1 could have an effect on peptide binding in the HLA-DR complex antigen binding
cleft that alters risk for the development of UC.
It is important to note that the MHC association signal in UC is complex and not completely
explained by amino acid position 11 in HLA-DRβ1. In fact, our forward stepwise model
selection identified 13 other terms besides rs9269955-C. This model is highly significant
with an overall P value of 4.28×10−40, but it will need to be validated in additional large
cohorts.
Included in our model was another missense SNP allele in HLA-DRB1, the T allele of
rs1136759. rs1136759 and two adjacent flanking SNPs encode variation at HLA-DRβ1,
amino acid 13, which is located in the P4 pocket of the HLA-DR complex antigen binding
cleft. The finding that two of the terms in the best model for prediction of UC risk relate to
the HLA-DRβ1 complex antigen binding cleft emphasizes the probable importance of HLA-
DRB1 in the pathogenesis of UC. Four other MHC class II loci variants, including SNPs in
HLA-DQB1 (rs1130380-C) and HLA-DRA (rs3135391), between HLA-DQA1 and HLA-
DQB1 (rs9273363), and between HLA-DQA2 and HLA-DQB2 (rs6933763), were
associated with UC in our multivariate model. The HLA-DRB, -DQB and -DPB genes are
all highly polymorphic and encode β-chains of the class II molecule αβ heterodimer while
the α-chains are encoded by the HLA-DQA, -DPA genes and -DRA genes.4
Three polymorphisms in MHC class III loci (rs440454, rs28435656, and rs915654) were
included as terms in our UC versus control model. The MHC class III region is one of the
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tmost gene dense regions in the human genome. Two of the SNPs in our model, rs440454
and rs28435656, are in linkage disequilibrium (r2 = 0.54 in HapMap 3-CEU11) and located
in an MHC class III segment that contains four genes within 30 kb including superkiller
viralicidic activity 2-like (SKIV2L) and RD RNA binding protein (RDBP).20 rs440454 is in
perfect linkage disequilibrium (r2 = 1.0 in HapMap 3-CEU11) with SNP rs419788 that was
associated with risk for lupus.21 rs28435656 is located in the complement component 2 (C2)
gene which is located immediately adjacent to the region that includes SKIV2L and RDBP.
Finally, rs915654 is located 5 prime to the lymphotoxin A (LTA) locus which has been
associated with CD and diabetes.22 All these findings suggest a role for MHC class III genes
in UC pathogenesis which warrants further investigation.
Another association of potential pathogenic interest identified in our UC versus control
model is rs2844677, a synonymous SNP in the coding region of the mucin 21, cell surface
associated (MUC21) gene. MUC21 is a recently identified gene that is expressed in normal
colon among other tissues and produces a transmembrane mucin involved in cell
adhesion.23, 24
In the last part of our analysis, we compared MHC region association signals between UC
and CD with ileal involvement. The finding that the 11 studied markers each had odds ratios
with effects in opposite directions for the two IBD phenotypes together with the results from
our initial association analysis in which the most significant associations in UC were
different than those for ileal CD, demonstrates that the association signals for UC and ileal
CD are quite different. This conclusion correlates with results of prior studies which have
shown that the only consistent associations with risk for both UC and CD have been for
HLA-DRB1*01:03 and HLA-B52.3, 4 In contrast, alleles of the HLA-DR2 split antigen
DR15 have been associated in opposite directions with HLA-DRB1*15:01 associated with
protection against CD and HLA-DRB1*15:02 associated with increased risk for UC.3, 5
In summary, we have performed detailed analyses to better understand MHC association
signals in UC and CD. Our most significant finding is that a specific variation at amino acid
position 11 of HLA-DRβ1, the only variable amino acid in the P6 pocket of the HLA-DR
complex antigen binding cleft, explains a substantial portion of the MHC association signal
and corresponds with several previously established classical HLA class II associations in
UC. The observed alteration at amino acid position 11 of HLA-DRβ1 may affect peptide
binding and result in an altered immune activation underlying protection against UC. We
have also developed a novel multivariate model that further defines the contribution of MHC
variation to risk for UC and highlights other genes of potential importance in UC
pathogenesis. Finally, our multivariate modeling suggests different effects of MHC
polymorphisms in UC and CD.
Materials and Methods
Study subjects
Our study sample included 574 UC, 630 CD with at least ileal involvement, and 1,508
control subjects of European ancestry that were recruited for genetic studies at the Cleveland
Clinic or the University of Pittsburgh under institutional review board-approved protocols.
All subjects provided written informed consent. IBD diagnoses and assessment of disease
location were confirmed by IBD physicians via review of primary medical records using
standard endoscopic, radiographic and histologic criteria.
Genotyping and quality control
Study subjects were genotyped using the Illumina Omni1-quad BeadChip (Illumina, San
Diego, CA) at the Feinstein Institute for Medical Research of the North Shore-Long Island
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tJewish Health System. Data from samples with preliminary genotype call rates > 0.98 using
cluster positions provided by Illumina were reclustered using the Illumina GenomeStudio
software, and the new cluster positions were applied to all samples. Initial quality control of
the genotyping data included removal of one sample from each pair with estimated identity-
by-descent proportion > 0.10, removal of samples with genotype missing rates > 0.05, or
with discordant SNP-determined and reported gender or ambiguous SNP-determined
gender, and removal of SNPs with genotype missing rates > 0.05, minor allele frequencies in
controls < 0.005, or Hardy-Weinberg P values in controls < 1×10−6. These quality control
steps were performed using the PLINK software.25 Subsequently, tag SNPs with genotype
missing rates < 0.1% and physical separation of at least 0.4 megabases (Mb) were used in
spectral analysis of ancestry that identified 929 controls with a relatively homogenous
‘European’ ancestral background. Additional SNPs with minor allele frequencies < 0.005 or
Hardy-Weinberg P values < 0.001 in these 929 controls were removed from the dataset.
Ancestry matching
To control for potential confounding due to variation in genetic ancestry, study subjects
were grouped into 11 approximately homogenous clusters, based on genetic distances
derived from GemTools.26, 27 Ancestry was inferred based on SNPs with genotype missing
rates < 0.1% and a physical separation of at least 0.2 Mb. In all of the association analyses,
we controlled for ancestry by including cluster membership as a blocking variable. The
inflation across the genome-wide SNP data was minimal (genomic control lambda28 = 1.02
for UC vs. control and 1.03 for CD with ileal involvement vs. control), confirming that the
samples were well matched.
Imputation of classical HLA, SNP, and amino acid allele dosages
We followed a previously described procedure29 to impute classical HLA alleles and their
corresponding amino acid sequences in our cases and controls, using the genotyped SNPs in
our GWAS as input. This imputation procedure is conceptually similar to HLA*IMP32 in
that haplotype information across the region is used to predict classical HLA alleles based
on genotyped SNPs. A prior study demonstrated empirical evidence that the imputations
have good accuracy29 reaching comparable levels of accuracy to the work on which
HLA*IMP is based.32
As the reference panel, we used a data set of 263 HLA-A, -B, -C, -DRB1, -DQA1, -DQB1, -
DPA1 and -DPB1 classical alleles at four-digit resolution, 3,852 SNPs, and 372 amino acid
positions in 2,767 unrelated founder individuals of European descent collected by the MHC
Working Group of the Type 1 Diabetes Genetics Consortium.30 All variants were encoded
as biallelic markers, allowing us to use standard tools for imputation. For variants with
greater than two alleles, each allele was coded as present or absent, and analyzed in a
separate test. We used default parameters for BEAGLE
(http://faculty.washington.edu/browning/beagle/beagle.html): ten iterations of phasing/
imputation, testing four pairs of haplotype pairs for each individual at each iteration. For
each variant, we used the posterior probabilities of carrying 0 (AA), 1 (AB) or 2 (BB) copies
to calculate the effective dosage for allele B (=2xPr(BB) + Pr(AB)). To obtain allele dosages
for MHC region Omni1-quad SNPs, we used BEAGLECALL.31 Three iterations of
BEAGLECALL were run, with increasing stringency of genotype calling filters
(callthreshold=0.9 and missingcohort=0.1 in iteration 1, callthreshold=0.98 and
missingcohort=0.02 in iteration 2, and callthreshold=0.985 and missingcohort=0.015 in
iteration 3). We combined dosage information for markers in the Type 1 Diabetes Genetics
Consortium reference panel with dosage information for additional Omni1-quad SNPs that
appeared in both genome builds NCBI36/hg18 and GRCh37/hg19 into a combined set of
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tgenetic features in the MHC region from 29,299 to 33,884 kilobases (kb) on chromosome 6
using NCBI36/hg18 coordinates.
HLA-DRB1 imputation quality at two-digit resolution was assessed by sequence-specific
oligonucleotide (SSO) probes and next-generation sequencing of genomic DNA collected
from 384 of our study subjects (see Supplementary Materials).
Association analyses
Association analyses were performed using allele dosage data from 562 UC, 611 CD with
ileal involvement, and 1,428 control samples that passed quality control. We examined the
association between binary markers in the HLA region and UC versus control and CD with
ileal involvement versus control using logistic regression with a log-additive model.
Forward stepwise model selection was used to determine a set of markers in the post
imputation data that jointly predicted disease versus control status, without including
multiple markers that were in tight linkage disequilibrium. Markers with an allele frequency
< 0.001 were excluded. The Bayesian Information Criterion (BIC) was used to find a model
that balanced model complexity with parsimony. The stepwise procedure started by taking
the best marker (lowest P value) into the regression model and iteratively adding markers
until the BIC ceased to improve. This procedure was performed in R
(http://www.r-project.org) using the “glm” and “step” functions.
For each polymorphic amino acid position in the HLA region we also conducted an omnibus
test for association using multivariate logistic regression with degrees-of-freedom equal to
the number of distinct residues for that amino acid position minus one. For the position
yielding the smallest P value we used stepwise regression, limited to that position, to select a
parsimonious model for the site.
Finally, using stepwise regression we determined a model for differentiating UC and CD
with ileal involvement. In this model, CD with ileal involvement subjects served as controls
and UC subjects served as cases.
For each multivariate model, we provide the P value associated with the best model. This P
value pertains to the null hypothesis that none of the terms in the model has any explanatory
value, versus the alternative hypothesis that at least one term is associated with the
phenotype. The degrees-of-freedom associated with this test equals the number of markers
in the multivariate model.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Major histocompatibility complex regional association plots for ulcerative colitis. (A)
Association results for genotyped SNPs from the Illumina Omni1-quad BeadChip. The
intensity of the red shading indicates the strength of the pairwise r2 correlation to the most
associated SNP, rs2647025. (B) Association results for both genotyped (◇ symbols) and
imputed (■ symbols) nucleotides focused in on the region of peak association in panel A.
Horizontal lines represent the classical HLA alleles in this region. The intensity of the red
shading indicates the strength of the pairwise r2 correlation to the most associated SNP
marker, rs9269955-C. (C) Association results for imputed amino acids in HLA-DRβ1.
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Major histocompatibility complex regional association plot for Crohn’s disease with ileal
involvement. Association results are for genotyped SNPs from the Illumina Omni1-quad
BeadChip. The intensity of the red shading indicates the strength of the pairwise r2
correlation to the most associated SNP, rs17880124.
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Table 2
Omnibus amino acid tests for ulcerative colitis versus control. Amino acid positions with omnibus P < 5 ×
10−8 are shown.
HLA amino acid position
Codon middle nucleotide position (chromosome 6, NCBI36/
hg18) Degrees of freedom Omnibus P value
HLA-DRβ1, amino acid 181 32,657,335 1 7.48 × 10−9
HLA-DRβ1, amino acid 104 32,657,566 1 4.70 × 10−12
HLA-DRβ1, amino acid 98 32,657,584 1 4.68 × 10−12
HLA-DRβ1, amino acid 37 32,660,037 4 1.46 × 10−8
HLA-DRβ1, amino acid 30 32,660,058 5 6.01 × 10−10
HLA-DRβ1, amino acid 13 32,660,109 5 1.39 × 10−10
HLA-DRβ1, amino acid 11 32,660,115 5 2.68 × 10−13
HLA-DQα1, amino acid 47 32,717,191 3 2.73 × 10−10
HLA-DQα1, amino acid 50 32,717,200 2 2.95 × 10−11
HLA-DQα1, amino acid 53 32,717,209 2 2.12 × 10−11
HLA-DQα1, amino acid 175 32,717,988 2 2.28 × 10−10
HLA-DQα1, amino acid 215 32,718,464 1 5.95 × 10−12
HLA-DQβ1, amino acid 185 32,737,733 1 8.62 × 10−11
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